| Targeting autophagy in disease: established and new strategies M Kocak, S Ezazi Erdi, G Jorba, I Maestro, J Farrés, V Kirkin, A Martinez, ... Autophagy 18 (3), 473-495, 2022 | 112 | 2022 |
| In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan G Jorba, J Aguirre-Plans, V Junet, C Segú-Vergés, JL Ruiz, A Pujol, ... PLoS One 15 (2), e0228926, 2020 | 39 | 2020 |
| Methods to Develop an in silico Clinical Trial: Computational Head-to-Head Comparison of Lisdexamfetamine and Methylphenidate JR Gutiérrez-Casares, J Quintero, G Jorba, V Junet, V Martínez, ... Frontiers in Psychiatry 12, 741170, 2021 | 16 | 2021 |
| Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach E Carcereny, A Fernández-Nistal, A López, C Montoto, A Naves, ... Oncotarget 12 (4), 316, 2021 | 16 | 2021 |
| A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis P Coto-Segura, C Segú-Vergés, A Martorell, D Moreno-Ramírez, G Jorba, ... Frontiers in Immunology 14, 1212981, 2023 | 1 | 2023 |
| The usage of transcriptomics datasets as sources of Real-World Data for clinical trialling P Matos-Filipe, JM García-Illarramendi, G Jorba, B Oliva, J Farrés, JM Mas bioRxiv, 2022.11. 10.515995, 2022 | 1 | 2022 |
| TPMS technology to infer biomarkers of macular degeneration prognosis in in silico simulated prototype-patients under the study of heart failure treatment with … G Jorba, J Aguirre-Plans, V Junet, C Segú-Vergés, JL Ruiz, A Pujol, ... bioRxiv, 625889, 2019 | 1 | 2019 |
| Comprehensive detection and characterization of human druggable pockets through novel binding site descriptors A Comajuncosa-Creus, G Jorba, X Barril, P Aloy bioRxiv, 2024.03. 14.584971, 2024 | | 2024 |
